Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CEBPA point mutations in hematological malignancies.

H Leroy1, C Roumier, P Huyghe

  • 1Laboratoire d'Hématologie A, CHRU Lille, U524 INSERM Lille, France.

Leukemia
|January 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[GATA2 gene mutations: 3 cases].

La Revue de medecine interne·2022
Same author

Effects of azacitidine in 93 patients with <i>IDH1/2</i> mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study.

Leukemia & lymphoma·2020
Same author

Immature platelet fraction (IPF): A reliable tool to predict peripheral thrombocytopenia.

Current research in translational medicine·2019
Same author

Pyoderma gangrenosum misdiagnosed as necrotising fasciitis or a real association between the two?

Journal of the European Academy of Dermatology and Venereology : JEADV·2019
Same author

[General medical practice and medicinal voluntary termination of pregnancy in Grand Est, France].

Revue d'epidemiologie et de sante publique·2018
Same author

Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.

Leukemia research·2018
Same journal

Lineage-restricted dependency on an oncofetal SNHG29-IGF2BP1 RNA axis in acute megakaryoblastic leukemia.

Leukemia·2026
Same journal

Selective targeting of RSK signaling with PMD-026 suppresses FLT3-activated acute myeloid leukemia while sparing normal hematopoiesis.

Leukemia·2026
Same journal

FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia.

Leukemia·2026
Same journal

Spatial remodeling of bone marrow architecture defines tissue-state signatures of disease activity and therapeutic response in myelodysplastic neoplasms.

Leukemia·2026
Same journal

Selective sensitivity of Ph-like B-cell acute lymphoblastic leukemia to BRG1 inhibition identifies a therapeutic vulnerability.

Leukemia·2026
Same journal

Unpacking the epigenetic landscape of acute lymphoblastic leukemia: resolving cellular heterogeneity and nutritional complexities.

Leukemia·2026
See all related articles

CCAAT/enhancer-binding protein-alpha (CEBPA) mutations are linked to a favorable prognosis in acute myeloid leukemia (AML), particularly within the intermediate-risk subgroup. Analyzing these mutations aids in AML prognosis assessment.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • CCAAT/enhancer-binding protein-alpha (CEBPA) is a key transcription factor in myelopoiesis.
  • CEBPA mutations have been identified in hematological malignancies.

Purpose of the Study:

  • To analyze the characteristics of CEBPA mutations.
  • To correlate CEBPA mutations with disease characteristics and prognosis in acute myeloid leukemia (AML).

Main Methods:

  • Systematic analysis of CEBPA mutations from reported studies.
  • Correlation of mutation characteristics with AML subtypes and prognostic classifications (WHO, FAB, MRC).

Main Results:

  • 146 CEBPA mutations were identified in 96 out of 1175 AML patients.

Related Experiment Videos

  • Mutations occurred throughout the gene, with clusters in N-terminal (out-of-frame) and C-terminal (in-frame) regions.
  • CEBPA mutations were associated with FAB subtypes M1, M2, M4 and the intermediate prognostic subgroup (MRC), conferring a favorable outcome.

    • Conclusions:

    • CEBPA mutations are exclusively found in AML and are associated with a favorable prognosis, similar to other specific genetic alterations.
    • Systematic analysis of CEBPA mutations can improve AML prognosis assessment, especially in intermediate-risk patients.